Publications

cemka > Publications

Classer les publications sur l'année

  • Économie de la santĂ©

    Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol,bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma : an analysis based on the United Kingdom general practitioner research database

    LAFUMA A, SALMON JF, ROBERT J, BERDEAUX G

    Clin Ophtalmol ; 2011;5:361-370

  • Économie de la santĂ©

    Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study

    ARMOIRY X, FAGNANI F, BENBOUBKER L, FACON T, FERMAND JP, HULIN C, MOREAU P, AULAGNER G

    J Clin Pharm Ther ; 2011;36(1):19-26

  • Économie de la santĂ©

    Le coĂ»t de l’asthme en France et les implications Ă©conomiques de son niveau de contĂŽle

    GADENNE S, PRIBIL C, CHOUAID C, VERGNENEGRE A, DETOURNAY B

    Rev Mal Respir ; 2011;28(4):419-426

  • Pharmaco-EpidĂ©miologie

    Instauration de l’insulinothĂ©rapie chez les diabĂ©tiques de type 2 en France : donnĂ©es de l’Ă©tude INSTIGATE

    CHARLES MA, CHARTIER F, BONNARD C, SMITH H, FAGNANI F, SALAUN-MARTIN C

    MĂ©decine des Maladies MĂ©taboliques ; 2011;5(2):189-198

  • Pharmaco-EpidĂ©miologie

    Five-year extension of a clinical trial comparing the EX-PRESS glaucoma filtration device and trabeculectomy in primary open-angle glaucoma

    DE JONG L, LAFUMA A, AGUADE AS, BERDEAUX G

    Clin Ophtalmol ; 2011;5:527-533

  • Pharmaco-EpidĂ©miologie

    Epidemiology of atrial fibrillation in France : extrapolation of international epidemiological data to France and analysis of french hospitalization data

    CHARLEMAGNE A, BLACHER J, COHEN A, COLLET JP, DIEVART F, DE GROOTE P, HANON O, LEENARDT A, PINEL JF, PISICA-DONOSE G, LE HEUZEY JY

    Arch Cardiovasc Dis ; 2011;104:115-124

  • Économie de la santĂ©

    Economic impact of use of chlorhexidine-impregnated sponge dressing for prevention of central line-associated infections in the United States

    YE X, RUPNOW M, BASTIDE P, LAFUMA A, OVINGTON L, JARVIS WR

    Am J Infect Control ; 2011;39(8):647-654

  • Pharmaco-EpidĂ©miologie

    Do two intravenous iron sucrose preparations have the same efficacy ?

    ROTTEMBOURG J, KADRI A, LEONARD E, DANSAERT A, LAFUMA A

    2011 - Nephrol Dial Transplant ; 26 - 10 : 3262-3267

  • Économie de la santĂ©

    Cost effectivenessof posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for theFrench healthcare system

    MICHALLET M, GANGNEUX JP, LAFUMA A, HERBRECHT R, RIBAUD P, CAILLOT D, DUPONT B, MOREAU P, BERGER P, O’SULLIVAN AK

    J Med Econ ; 2011;14(1):28-35

  • Économie de la santĂ©

    Comparison of outcomes with multifocal intraocular lenses : A meta-analysis

    COCHENER B, LAFUMA A, KHOSHNOOD B, COUROUVE L, BERDEAUX G

    Clin Ophtalmol ; 2011;5:45-56

  • Pharmaco-EpidĂ©miologie

    Biomechanical and psychosocial work exposures and musculoskeletal symptoms among vineyard workers

    BERNARD C, COUROUVE L, BOUEE S, ADJEMIAN A, CHRETIEN JC, NIEDHAMMER I

    J Occup Health ; 2011;53:297-311

  • Pharmaco-EpidĂ©miologie

    Type 2 diabetes treatment intensification in general practice in France in 2008-2009 : the DIAttitude Study

    BALKAU B, BOUEE S, AVIGNON A, VERGES B, CHARTIER I, AMELINEAU E, HALIMI S

    Diabetes Metab ; 2012;38:29-35

  • Pharmaco-EpidĂ©miologie

    Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010 : the DIAttitude Study

    HALIMI S, BALKAU B, ATTALI C, DETOURNAY B, AMELINEAU E, BLICKLE JF

    Diabetes Metab ; 2012;38:36-46

  • Pharmaco-EpidĂ©miologie

    Prise en charge du purpura thrombopénique immunologique en France avant la mise à disposition des agonistes du récepteur à la thrombopoïétine

    MICHEL M, DOZ M, LECLERC-TEFFAHI S, DETOURNAY B, LEVY-BACHELOT L

    Rev Med Interne ; 2012;33:305–310

  • Pharmaco-EpidĂ©miologie

    Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007)

    BOURLIERE M, OUZAN D, ROSENHEIM M, DOFFOËL M, MARCELLIN P, PAWLOTSKY JM, SALOMON L, FAGNANI F, ROUANET S, PINTA A, VRAY M
    SALOMON L, FAGNANI F, ROUANET S, PINTA A, VRAY M

    Antivir Ther ; 2012;17(1):101-110